Stemtech OTC Stock Performance

STEK
 Stock
  

USD 0.16  0.01  6.67%   

The entity has a beta of -0.0241, which indicates not very significant fluctuations relative to the market. Let's try to break down what Stemtech's beta means in this case. As returns on the market increase, returns on owning Stemtech are expected to decrease at a much lower rate. During the bear market, Stemtech is likely to outperform the market. Even though it is essential to pay attention to Stemtech current price movements, it is always good to be careful when utilizing equity historical returns. Our philosophy towards measuring any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Stemtech exposes twenty-one different technical indicators, which can help you to evaluate its performance. Stemtech has an expected return of -3.56%. Please be advised to validate Stemtech information ratio, as well as the relationship between the potential upside and kurtosis to decide if Stemtech performance from the past will be repeated at some point in the near future.
  
Stemtech Performance
0 of 100
Over the last 90 days Stemtech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's technical and fundamental indicators remain fairly strong which may send shares a bit higher in January 2023. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more

Stemtech Price Channel

Begin Period Cash Flow133065.00
Free Cash Flow-1914093.00

Stemtech Relative Risk vs. Return Landscape

If you would invest  277.00  in Stemtech on September 8, 2022 and sell it today you would lose (261.00)  from holding Stemtech or give up 94.22% of portfolio value over 90 days. Stemtech is currently does not generate positive expected returns and assumes 12.1834% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Stemtech, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Stemtech is expected to under-perform the market. In addition to that, the company is 8.02 times more volatile than its market benchmark. It trades about -0.29 of its total potential returns per unit of risk. The NYSE Composite is currently generating roughly 0.03 per unit of volatility.

Stemtech Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Stemtech's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Stemtech, and traders can use it to determine the average amount a Stemtech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.2925

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsSTEK
Estimated Market Risk
 12.18
  actual daily
 
 96 %
of total potential
 
9696
Expected Return
 -3.56
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.29
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Stemtech is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Stemtech by adding it to a well-diversified portfolio.

About Stemtech Performance

To evaluate Stemtech OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Stemtech generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Stemtech OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Stemtech market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Stemtech's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.

Things to note about Stemtech

Checking the ongoing alerts about Stemtech for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Stemtech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Stemtech Alerts

Equity Alerts and Improvement Suggestions

Stemtech generated a negative expected return over the last 90 days
Stemtech has high historical volatility and very poor performance
Stemtech has some characteristics of a very speculative penny stock
Stemtech has high likelihood to experience some financial distress in the next 2 years
The company currently holds 219.47 K in liabilities. Stemtech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Stemtech until it has trouble settling it off, either with new capital or with free cash flow. So, Stemtech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stemtech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stemtech to invest in growth at high rates of return. When we think about Stemtech's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 4.32 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 3.3 M.
Stemtech currently holds about 399.73 K in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
Roughly 64.0% of the company outstanding shares are owned by corporate insiders
Additionally, take a look at World Market Map. Note that the Stemtech information on this page should be used as a complementary analysis to other Stemtech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Stemtech OTC Stock analysis

When running Stemtech price analysis, check to measure Stemtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stemtech is operating at the current time. Most of Stemtech's value examination focuses on studying past and present price action to predict the probability of Stemtech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Stemtech's price. Additionally, you may evaluate how the addition of Stemtech to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Please note, there is a significant difference between Stemtech's value and its price as these two are different measures arrived at by different means. Investors typically determine Stemtech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stemtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.